section name header

Indications

High Alert

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, bradycardia.

Derm: flushing, sweating.

EENT: blurred vision, diplopia, miosis.

Endo: adrenal insufficiency.

GI: constipation, dry mouth, nausea, vomiting.

GU: urinary retention.

Neuro: confusion, sedation, dizziness, dysphoria, euphoria, floating feeling, hallucinations, headache, unusual dreams.

Resp: RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).

Misc: physical dependence, psychological dependence, tolerance.

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

see Calculator

Doses depend on level of pain and tolerance. Larger doses may be required during chronic therapy

Hepatic Impairment

Renal Impairment

US Brand Names

Dilaudid, Dilaudid-HP, Exalgo

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists

Pharmacokinetics

Absorption: Well absorbed following oral, rectal, SUBQ, and IM administration. Extended-release product results in an initial release of drug, followed by a 2nd sustained phase of absorption.

Distribution: Widely distributed. Crosses the placenta; enters breast milk.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-life: Oral (immediate-release), or injection: 2–4 hr; Oral (extended-release): 8–15 hr.

Contr. Subst. Schedule

Schedule II (C-II)

Canadian Brand Names

Hydromorph Contin

Time/Action Profile

(analgesic effect)

ROUTEONSETPEAKDURATION
PO-IR30 min30–90 min4–5 hr
PO-ERunknownunknownunknown
SUBQ15 min30–90 min4–5 hr
IM15 min30–60 min4–5 hr
IV10–15 min15–30 min2–3 hr
Rect15–30 min30–90 min4–5 hr

Patient/Family Teaching

Pronunciation

hye-droe-MOR-fone audio

Code

NDC Code*